Inhibikase Therapeutics, Inc.
IKT
$1.67
-$0.01-0.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 295.12% | -133.94% | 82.57% | 71.37% | -83.53% |
| Gross Profit | -295.12% | 133.94% | -82.57% | -71.37% | 83.53% |
| SG&A Expenses | 40.52% | 18.13% | 242.67% | 199.78% | 158.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.56% | -55.65% | 127.56% | 114.48% | 229.60% |
| Operating Income | -15.56% | 55.65% | -127.56% | -114.48% | -229.60% |
| Income Before Tax | -19.75% | -4.96% | -106.47% | -99.93% | -194.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.75% | -4.96% | -106.47% | -99.93% | -194.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.75% | -4.96% | -106.47% | -99.93% | -194.19% |
| EBIT | -15.56% | 55.65% | -127.56% | -114.48% | -229.60% |
| EBITDA | -15.55% | 55.63% | -127.41% | -114.28% | -229.79% |
| EPS Basic | 37.76% | 38.80% | 79.63% | 83.26% | 79.16% |
| Normalized Basic EPS | 41.31% | 77.47% | 78.80% | 83.25% | 77.39% |
| EPS Diluted | 37.76% | 38.80% | 79.63% | 83.26% | 79.16% |
| Normalized Diluted EPS | 41.31% | 77.47% | 78.80% | 83.25% | 77.39% |
| Average Basic Shares Outstanding | 92.44% | 71.55% | 913.79% | 1,094.44% | 1,312.10% |
| Average Diluted Shares Outstanding | 92.44% | 71.55% | 913.79% | 1,094.44% | 1,312.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |